Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Debt to Equity (2021 - 2025)

Arcutis Biotherapeutics has reported Debt to Equity over the past 5 years, most recently at $0.58 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.58 for Q4 2025, down 15.49% from a year ago — trailing twelve months through Dec 2025 was $0.58 (down 15.49% YoY), and the annual figure for FY2025 was $0.58, down 15.49%.
  • Debt to Equity for Q4 2025 was $0.58 at Arcutis Biotherapeutics, down from $0.69 in the prior quarter.
  • Over the last five years, Debt to Equity for ARQT hit a ceiling of $4.3 in Q3 2023 and a floor of $0.24 in Q4 2021.
  • Median Debt to Equity over the past 5 years was $0.78 (2025), compared with a mean of $1.17.
  • Biggest five-year swings in Debt to Equity: soared 562.87% in 2023 and later crashed 70.1% in 2024.
  • Arcutis Biotherapeutics' Debt to Equity stood at $0.24 in 2021, then surged by 288.25% to $0.94 in 2022, then soared by 141.19% to $2.28 in 2023, then crashed by 70.1% to $0.68 in 2024, then decreased by 15.49% to $0.58 in 2025.
  • The last three reported values for Debt to Equity were $0.58 (Q4 2025), $0.69 (Q3 2025), and $0.78 (Q2 2025) per Business Quant data.